CEO
Engimata
Dr. Mitra Mosharraf brings over two decades of seasoned expertise to the forefront of biotechnological drug product development of proteins, antibodies, peptides, Antibody-Drug Conjugates (ADCs), liposomes, and vaccines. As a co-founder and CEO of Engimata Inc., she spearheads the innovation of cutting-edge liposomal vaccine adjuvants. In her concurrent role as the Chief Scientific Officer at HTD Biosystems, a reputable Contract Development Organization, Dr. Mosharraf is instrumental in steering the research and development of biopharmaceuticals. Her leadership and strategic guidance serve a broad spectrum of over 300 organizations worldwide. In her tenures at globally acclaimed corporations such as Pfizer, Pharmacia, and Santen, she led the advancement of combination products in dual chamber syringes and the development of ophthalmic biologic products for intravitreal injections.
Her scholarly pursuits are deeply rooted in exploring the molecular interactions, particularly in solid states, and their critical role in the formulation of stable, efficacious nanotechnology-driven and biologic drug products, including vaccines. Dr. Mosharraf's innovative research endeavors have culminated in the awarding of six patents and the publication of over 15 peer-reviewed scientific papers.
An active member of the American Association of Pharmaceutical Scientists (AAPS), she has held leadership roles including vice chair of the AAPS Nanotechnology Community and chair of the Bay Area Discussion Group. Her academic credentials are robust, with a PhD and MS in Pharmaceutical Sciences from Uppsala University, an MBA from MIT Sloan School of Management, and certificates in Business Analytics, AI in Biotech, and Executive Leadership from MIT and Cornell.
Licensed as a pharmacist by the Swedish National Board of Health & Welfare, Dr. Mosharraf is trilingual and has an international footprint, living and working across Asia, Europe, and the US. Based in the San Francisco Bay Area, she enjoys the outdoors and tennis, embodying a balance between professional dedication and personal well-being.